. Effect of ruxolitinib treatment on cytokines and growth factors ii. Table S2 . Baseline demographic and biologic characteristics of patients analyzed for leukocyte alkaline phosphatase (LAP) expression iii. Table S3 7. Able to comprehend and willing to sign an informed consent form.
8. Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.
Exclusion Criteria
1. Women who were pregnant or breastfeeding.
2. Use of interferon-alpha or anagrelide within 7 days or hydroxyurea within 1 day of enrollment. All other cytoreductive therapies for PV or investigational medications must have been discontinued within 28 days of enrollment.
3. Patients with a history of another malignancy. Exceptions to this rule were patients who had cervical intraepithelial neoplasia or basal or squamous cell skin cancer and showed no evidence of recurrence. 7. Clinically significant cardiac disease (New York Heart Association Class III or IV).
8. Incomplete recovery from any prior surgical procedures or had surgery within 4 weeks before study entry.
9. Presence of acute active infection requiring antimicrobials.
10. Prior treatment with any oral Janus kinase (JAK) inhibitor was not permitted unless agreed to by both the investigator and the sponsor.
Study Design
Six to eight patients were randomized to 1 of 3 ruxolitinib dose-finding cohorts: 10 mg twice daily, 25 mg twice daily, or 50 mg once daily. The dose-expansion cohort was determined not on the basis of predefined statistical analyses, but on a general review by both the sponsor and the investigators of efficacy and safety data of patients enrolled in the dose-finding cohorts who completed at least 56 days of treatment. Dosing was withheld if hematocrit was < 30%, absolute neutrophil count was < 0.7510 9 /L, or platelet count was < 5010 9 /L, or for any grade > 3 nonhematologic AE that, in the investigator's opinion, was related to treatment. Patients continued on therapy indefinitely, provided they had no evidence of disease progression and were receiving clinical benefit, as judged by the investigator. Analyses/microRNA expression).
2,3
The study was approved by institutional review boards of participating institutions and was conducted in accordance with the Declaration of Helsinki, as described in the International Conference on Harmonization Guidelines for Good Clinical Practice, and applicable regulatory requirements. All patients provided written informed consent.
Original Protocol-Defined Response Evaluation
The primary efficacy end point for PV was the percentage of patients reaching 
Pharmacodynamic and Molecular Analyses

Measurement of phosphorylated signal transducers and activators of transcription (STAT)3 and JAK2V617F allele burden:
Changes in JAK2V617F allele burden in whole blood during therapy were measured according to Levine et al. 8 Whole blood collected at baseline and at different times after treatment was used for the evaluation of phosphorylated STAT3 by ELISA (R&D Systems, Inc., Minneapolis, MN). The phosphorylated STAT3 assay was chosen because it is a more robust assay compared with the phosphorylated STAT5 assay and because it is an optimal assay for measuring JAK1 inhibition. As the potency of ruxolitinib in inhibiting JAK1 and JAK2 is very similar, the pSTAT3 assay would indicate levels of inhibition for both JAK1 and JAK2. The time points for analysis were post-ruxolitinib dosing (peak) and prior to the next ruxolitinib dose (trough). Cytokines and inflammatory markers were assessed in plasma collected at baseline and at different times after treatment using the Luminex multiplex beadbased assay system (Luminex, Austin, TX). Milliplex assay reagents were obtained from Millipore Corporation (Billerica, MA), with assays performed as described by the manufacturer.
Granulocyte activation
Flow cytometry immunophenotyping was utilized to measure leukocyte alkaline phosphatase (LAP) expression on circulating leukocytes as previously described, 9 and data were expressed as mean fluorescence intensity ratio. Peripheral blood samples were collected at baseline (before starting any therapy) and after 1, 2, 6, 9, 12, and 15 months of treatment. Total cellular RNA, including small RNAs, was extracted using RNeasy Micro kit (Qiagen, Valencia, CA) following the protocol supplied by the manufacturer. Disposable RNA chips (Agilent RNA 6000 Nano LabChip kit, Agilent Technologies, Waldbrunn, Germany) were used to determine the purity/integrity of RNA samples using Agilent 2100 Bioanalyzer. NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) was used to evaluate the RNA sample concentration, and 260/280 and 260/230 nm ratios were considered to verify the purity of total RNA. Total RNA (500 ng for samples) was labeled using the FlashTag Median white blood cell count, 10 Figure S1 . Kaplan-Meier plot of time to discontinuation from study. Twenty-six of 34 patients (76%) remained on study for at least 144 weeks. Phosphorylated STAT3 (pSTAT3) levels following ruxolitinib treatment. Basal pSTAT3 levels in whole blood of patients with polycythemia vera (n = 6) and healthy controls (n = 10) were similar (left side). After interleukin-6 stimulation (right side), the magnitude of increase in pSTAT3 levels was greater in patients with polycythemia vera versus healthy controls;
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however, these levels reduced during ruxolitinib treatment and approached levels of healthy controls at days 15 and 29. showed that 14 microRNAs were differentially expressed in response to ruxolitinib treatment. Of these, 12 microRNAs increased and 2 decreased. ANOVA, analysis of variance; miR, microRNA; PV, polycythemia vera; SC, screening; TR, treatment.
